Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. (Arcutis) has announced a tender offer to exchange certain outstanding options for new restricted stock units (RSUs) under its 2020 Equity Incentive Plan. The offer, detailed in a Schedule TO filed with the SEC, is aimed at eligible employees and consultants holding options with exercise prices equal to or greater than $10.00. The exchange ratios vary based on the exercise price of the options and are designed to balance compensatory goals with shareholder interests. Non-employee board members are not eligible to participate. The offer, which commenced on January 16, 2024, will expire at 8:59 P.M. Pacific Time on February 12, 2024, unless extended. The Replacement RSU Awards will be granted upon cancellation of the accepted options, with vesting based on continued employment or service. The offer is subject to certain conditions, including regulatory approvals and market conditions. As of January 12, 2024, the closing price of Arcutis Common Stock on Nasdaq was $3.64 per share.
Arcutis Biotherapeutics, Inc. (Arcutis) has announced a tender offer to exchange certain outstanding options for new restricted stock units (RSUs) under its 2020 Equity Incentive Plan. The offer, detailed in a Schedule TO filed with the SEC, is aimed at eligible employees and consultants holding options with exercise prices equal to or greater than $10.00. The exchange ratios vary based on the exercise price of the options and are designed to balance compensatory goals with shareholder interests. Non-employee board members are not eligible to participate. The offer, which commenced on January 16, 2024, will expire at 8:59 P.M. Pacific Time on February 12, 2024, unless extended. The Replacement RSU Awards will be granted upon cancellation of the accepted options, with vesting based on continued employment or service. The offer is subject to certain conditions, including regulatory approvals and market conditions. As of January 12, 2024, the closing price of Arcutis Common Stock on Nasdaq was $3.64 per share.
Arcutis Biotherapeutics, Inc.（Arcutis）宣布了一项要约，根据其2020年股权激励计划，将某些未偿还期权交换为新的限制性股票单位（RSU）。该要约详见向美国证券交易委员会提交的附表TO，目标是持有行使价等于或大于10.00美元的期权的符合条件的员工和顾问。交换比率因期权行使价而异，旨在平衡补偿目标与股东利益。非雇员董事会成员没有资格参加。该优惠于2024年1月16日开始，除非延期，否则将于太平洋时间2024年2月12日晚上 8:59 到期。替代RSU奖励将在取消已接受的期权后发放，并根据继续就业或服务进行归属。该报价受某些条件的约束，包括监管部门的批准和市场条件。截至2024年1月12日，纳斯达克Arcutis普通股的收盘价为每股3.64美元。
Arcutis Biotherapeutics, Inc.（Arcutis）宣布了一项要约，根据其2020年股权激励计划，将某些未偿还期权交换为新的限制性股票单位（RSU）。该要约详见向美国证券交易委员会提交的附表TO，目标是持有行使价等于或大于10.00美元的期权的符合条件的员工和顾问。交换比率因期权行使价而异，旨在平衡补偿目标与股东利益。非雇员董事会成员没有资格参加。该优惠于2024年1月16日开始，除非延期，否则将于太平洋时间2024年2月12日晚上 8:59 到期。替代RSU奖励将在取消已接受的期权后发放，并根据继续就业或服务进行归属。该报价受某些条件的约束，包括监管部门的批准和市场条件。截至2024年1月12日，纳斯达克Arcutis普通股的收盘价为每股3.64美元。
有用
没用